Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Management of Invasive Ductal Carcinoma of the Breast

Introduction to Invasive Ductal Carcinoma Management

  • The American Cancer Society recommends breast-conserving surgery (BCS) with radiation therapy as the preferred approach for most patients with invasive ductal carcinoma when negative margins can be achieved with acceptable cosmesis, providing equivalent survival to mastectomy with superior quality of life 1, 2

Surgical Management

  • The American College of Surgeons suggests that tumor characteristics, such as localized disease ≤4 cm without gross multicentricity or diffuse malignant calcifications, are indications for breast-conserving surgery (BCS) 3
  • The National Comprehensive Cancer Network recommends that margin status, including the ability to achieve negative surgical margins with acceptable cosmetic outcome, is a crucial factor in deciding between BCS and mastectomy 1, 2
  • Patient factors, such as willingness to undergo radiation therapy and ability to comply with follow-up, should be considered when deciding on BCS 3, 2

Indications for Mastectomy

  • The American Cancer Society states that prior therapeutic radiation to the breast or chest wall is an absolute contraindication to BCS 3
  • Active collagen vascular disease, particularly scleroderma or systemic lupus erythematosus, is an absolute contraindication to BCS due to the risk of severe radiation toxicity 3
  • Pregnancy is a contraindication to radiation therapy, making mastectomy a preferred option 3

Breast Cancer Screening

  • The American College of Radiology recommends annual screening mammography starting at age 40-50 years, depending on risk factors 1
  • Bilateral mammography is required to evaluate the contralateral breast 4

Adjuvant Therapy

  • The National Comprehensive Cancer Network suggests that adjuvant endocrine therapy should be based on hormone receptor status (ER/PR positive) 1, 6
  • Adjuvant chemotherapy should be based on tumor biology, stage, and recurrence risk 1, 6

Follow-Up Post-Treatment

  • The American Cancer Society recommends clinical follow-up every 3-6 months for the first 3 years, every 6-12 months for years 4-5, and annually after 5 years 1
  • Annual mammography (bilateral) is recommended for surveillance 1

Specimen Handling and Pathologic Evaluation

  • The College of American Pathologists recommends that specimen radiography should be performed if microcalcifications are present 5, 2
  • The specimen should be oriented for the pathologist with sutures, and margins should be marked with India ink 7, 5

REFERENCES

1

Management of Invasive Ductal Carcinoma (IDC) of the Breast [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Treatment Approach for Invasive Distal Carcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Treatment for 1cm Invasive Ductal Carcinoma Behind the Areola [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025